Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

MRD Status in AML

January 10th 2019

Liposomal Daunorubicin & Cytarabine for AML

January 10th 2019

Glasdegib for AML

January 10th 2019

Considerations for Treating With Venetoclax in AML

January 10th 2019

Venetoclax for AML

January 10th 2019

High-Dose Anthracycline Therapy in AML

January 10th 2019

Updates on Chemotherapy Regimens in AML

January 10th 2019

Leukapheresis in AML

January 10th 2019

Dr. Cho on Ongoing Research With Checkpoint Inhibitors in Myeloma

January 10th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses ongoing research with checkpoint inhibitors in multiple myeloma.

The Future of AML Therapy: Cause for Optimism

January 8th 2019

IDH Inhibitors in AML Therapy

January 8th 2019

BTK/BCL2 Inhibitors & Other Novel Agents in CLL Therapy

January 8th 2019

Treatment Options for Relapsed/Refractory AML

January 8th 2019

Treatment Options for Relapsed/Refractory CLL

January 8th 2019

Venetoclax-Based Regimens as First-Line Therapy in AML

January 8th 2019

Venetoclax-Based Regimens as First-Line Therapy in CLL

January 8th 2019

Glasdegib, Gilteritinib, and Quizartinib Against AML

January 8th 2019

Venetoclax for CLL After Progression on 1 Prior Therapy

January 8th 2019

Midostaurin Plus Chemotherapy for FLT3-Mutated AML Cases

January 8th 2019

Efficacy and Safety of Ibrutinib-Containing Regimens in CLL

January 8th 2019